Industry still facing Problems with Root Cause Investigations
Recommendation
12-14 November 2024
Barcelona, Spain
Data Governance and Auditing the Analytical Process from Sampling to Reportable Value
Deviations and CAPA are still important issues during inspections. Inspectors' summaries of their observations show that things do not always work as they should. This also applies to root cause investigations. A look at the FDA's so-called 483s is also interesting here. The observations made by the inspector during an inspection are listed on the FDA Form 483. What many people do not know is that FDA summarises results from the 483s in tables and publishes them in their overview entitled "Inspection Observations".
According to the current file, 349 corresponding forms were issued in the area of "Drugs" in fiscal year 2020. With 79 observations, violations of section 21 CFR 211.192 ("Investigations of discrepancies, failures") are in second place. Primarily, this concerns problems and failures in the review of unexplained deviations and specifications that have not been met. The "Written record of investigation" required in the same paragraph was objected to 28 times. Here, written records of investigations do not always include conclusions and follow-up, or are not even present.
Related GMP News
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines